Biopolym. Cell. 2018; 34(5):350-360.
Структура и функции биополимеров
Нейропротекторный эффект рекомбинантного лейкемия-ингибирующего фактора человека у мышей с экспериментальной купризоновой моделью рассеянного склероза: возможные механизмы
1Лабунец И. Ф., 1Родниченко А. Е., 1Мельник Н. А., 1, 2Рымарь С. Е., 1Утко Н. А., 1Гаврилюк-Скиба Г. А., 1Бутенко Г. М.
  1. Государственное учреждение «Институт генетической и регенеративной медицины НАМН Украины»
    ул. Вышгородская, 67, Киев, Украина, 04114
  2. Институт молекулярной биологии и генетики НАН Украины
    ул. Академика Заболотного, 150, Киев, Украина, 03143

Abstract

Цель. Исследовать влияние рекомбинантного лейкемия- ингибирующего фактора человека (rhLIF) на структурные и функциональные изменения ЦНС в экспериментальной модели рассеянного склероза, индуцированного у мышей купризоном; оценить участие макрофагов, Т-лимфоцитов и антиоксидантных ферментов головного мозга в реализации его проявлений. Методы. Молодые мыши линии 129/Sv получали нейротоксин купризон с пищей ежедневно в течение 3-х недель, rhLIF – с 8-го дня приема купризона ежедневно в дозе 50 мкг/кг. Методы: гистологический, проточной цитометрии, спектрофотометрический и функциональный. Результаты. Прием купризона вызывает увеличение числа нейронов с деструктивными изменениями в головном и спинном мозге, количества макрофагов, СD3+-клеток и содержания малонового диальдегида в головном мозге; наблюдается снижение активности супероксиддисмутазы, глютатионпероксидазы в головном мозге и изменение поведения животных. Инъекции rhLIF частично или полностью восстанавливают измененные купризоном показатели. Эффект цитокина сохраняется через 2 мес после завершения эксперимента. Выводы. Нейропротекторный эффект rhLIF связан с подавлением индуцированных купризоном изменений в активности антиоксидантных ферментов, количестве Т-клеток и макрофагов в головном мозге.
Keywords: купризон, LIF, нейрон, Т-лимфоциты, макрофаги, антиоксидантные ферменты

References

[1] Wegner C, Esiri MM, Chance SA, Palace J, Matthews PM. Neocortical neuronal, synaptic, and glial loss in multiple sclerosis. Neurology. 2006;67(6):960-7.
[2] Loma I, Heyman R. Multiple sclerosis: pathogenesis and treatment. Curr Neuropharmacol. 2011;9(3):409-16.
[3] Lindvall O, Kokaia Z. Stem cells in human neurodegenerative disorders--time for clinical translation? J Clin Invest. 2010;120(1):29-40.
[4] Auernhammer CJ, Melmed S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev. 2000;21(3):313-45.
[5] Bauer S, Patterson PH. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. J Neurosci. 2006;26(46):12089-99.
[6] Ostasov P, Houdek Z, Cendelin J, Kralickova M. Role of leukemia inhibitory factor in the nervous system and its pathology. Rev Neurosci. 2015;26(4):443-59.
[7] Nicola NA, Babon JJ. Leukemia inhibitory factor (LIF). Cytokine Growth Factor Rev. 2015;26(5):533-44.
[8] Buono KD, Vadlamuri D, Gan Q, Levison SW. Leukemia inhibitory factor is essential for subventricular zone neural stem cell and progenitor homeostasis as revealed by a novel flow cytometric analysis. Dev Neurosci. 2012;34(5):449-62.
[9] Li Y, Zang D. The neuron regrowth is associated with the proliferation of neural precursor cells after leukemia inhibitory factor administration following spinal cord injury in mice. PLoS One. 2014;9(12):e116031.
[10] Deverman BE, Patterson PH. Exogenous leukemia inhibitory factor stimulates oligodendrocyte progenitor cell proliferation and enhances hippocampal remyelination. J Neurosci. 2012;32(6):2100-9.
[11] Praet J, Guglielmetti C, Berneman Z, Van der Linden A, Ponsaerts P. Cellular and molecular neuropathology of the cuprizone mouse model: clinical relevance for multiple sclerosis. Neurosci Biobehav Rev. 2014;47:485-505. Review.
[12] González H, Pacheco R. T-cell-mediated regulation of neuroinflammation involved in neurodegenerative diseases. J Neuroinflammation. 2014;11:201.
[13] Sugiura S, Lahav R, Han J, Kou SY, Banner LR, de Pablo F, Patterson PH. Leukaemia inhibitory factor is required for normal inflammatory responses to injury in the peripheral and central nervous systems in vivo and is chemotactic for macrophages in vitro. Eur J Neurosci. 2000;12(2):457-66.
[14] Gudi V, Gingele S, Skripuletz T, Stangel M. Glial response during cuprizone-induced de- and remyelination in the CNS: lessons learned. Front Cell Neurosci. 2014;8:73.
[15] Banner LR, Patterson PH, Allchorne A, Poole S, Woolf CJ. Leukemia inhibitory factor is an anti-inflammatory and analgesic cytokine. J Neurosci. 1998;18(14):5456-62.
[16] Acs P, Selak MA, Komoly S, Kalman B. Distribution of oligodendrocyte loss and mitochondrial toxicity in the cuprizone-induced experimental demyelination model. J Neuroimmunol. 2013;262(1-2):128-31.
[17] Labunets IF, Melnyk NO, Kuzminova IA, Butenko GM. Pat N 94458 UA (G09B 23. 28 (2006.01)), "Modeling of the structural changes of the central nervous system neurons in demyelinating diseases" N u 2014 06622; publ. 11.10.2014, Bull. N 21.
[18] Xuan Y, Yan G, Wu R, Huang Q, Li X, Xu H. The cuprizone-induced changes in (1)H-MRS metabolites and oxidative parameters in C57BL/6 mouse brain: Effects of quetiapine. Neurochem Int. 2015;90:185-92.
[19] Rymar SE, Novikova SN, Irodov DM, Bazalii AV, Sukhorada EM, Kordum VA. Leukemia inhibitory factor: perspectives for use in medicine and development of its producer. J NAMS Ukraine. 2010; 16:199-212.
[20] Marriott MP, Emery B, Cate HS, Binder MD, Kemper D, Wu Q, Kolbe S, Gordon IR, Wang H, Egan G, Murray S, Butzkueven H, Kilpatrick TJ. Leukemia inhibitory factor signaling modulates both central nervous system demyelination and myelin repair. Glia. 2008;56(6):686-98.
[21] Labunets IF, Melnyk NO, Rymar SYu. Pat N 104976 UA (G09B 23. 28 (2006.01)) "Modeling of regeneration of damaged brain neurons during neurodegenerative diseases”, N u 2015 09252; publ. 02.25.2016, Bull N 4.
[22] Labunets IF, Melnyk NO, Kuzminova IA, Pod’iachenko EV, Butenko GM. Effect of neurotoxin "cuprizone" on behavioral reactions and morphofunctional changes of cerebral and spinal cord neurons in mice. J NAMS Ukraine. 2014; 20(4):402-8.
[23] Amikishieva AV. Behavioral phenotyping: modern methods and equipment. Vestnik VOGiS. 2009; 13:529-42.
[24] Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem. 1978;86(1):271-8.
[25] Muradian KhK, Utko NA, Mozzhukhina TG, Pishel' IN, Litoshenko AIa, Bezrukov VV, Fraĭfel'd VE. [Correlative links between superoxide dismutase, catalase and glutathione peroxidase activities in mouse liver]. Ukr Biokhim Zh (1999). 2003;75(1):33-7.
[26] Guillemin GJ, Brew BJ. Microglia, macrophages, perivascular macrophages, and pericytes: a review of function and identification. J Leukoc Biol. 2004;75(3):388-97.
[27] Jordan FL, Wynder HJ, Booth PL, Thomas WE. Method for the identification of brain macrophages/phagocytic cells in vitro. J Neurosci Res. 1990;26(1):74-82.
[28] Preclinical studies of drugs (guidelines). Ed. OV Stephanov. Kiev: Avicenna, 2001. 528 p.
[29] Lakin GF. Biometrics. Moscow: High School Publ. 1990, 350 p.
[30] Labunets IF, Melnyk NO, Rodnichenko AE, Rymar SE, Utko NA. Cuprizone-Induced Disorders of Central Nervous System Neurons, Behavioral Reactions, Brain Activity of Macrophages and Antioxidant Enzymes in the Mice of Different Ages: Role of Leukemia Inhibitory Factor in their Improvement. J Aging Geriatr Med. 2017; 1:2.
[31] Ganong V,F. Human physiology. Lviv: BaK, 2002. 784 p.
[32] Lynch MA. Age-related neuroinflammatory changes negatively impact on neuronal function. Frontiers in Aging Neuroscience. 2010; 1,
[33] Kang Z, Liu L, Spangler R, Spear Ch, Wang Ch, Gulen MF, Veenstra M, Ouyang W, Ransohoff RM, Li X. IL-17-induced Act1-mediated signalling is critical for cuprizone-induced demyelination. J Neurosci. 2012; 32(4):8284-92.
[34] Vanderlocht J, Hellings N, Hendriks JJ, Vandenabeele F, Moreels M, Buntinx M, Hoekstra D, Antel JP, Stinissen P. Leukemia inhibitory factor is produced by myelin-reactive T cells from multiple sclerosis patients and protects against tumor necrosis factor-alpha-induced oligodendrocyte apoptosis. J Neurosci Res. 2006;83(5):763-74.
[35] Cao W, Yang Y, Wang Z, Liu A, Fang L, Wu F, Hong J, Shi Y, Leung S, Dong C, Zhang JZ. Leukemia inhibitory factor inhibits T helper 17 cell differentiation and confers treatment effects of neural progenitor cell therapy in autoimmune disease. Immunity. 2011;35(2):273-84.
[36] Chollangi S, Wang J, Martin A, Quinn J, Ash JD. Preconditioning-induced protection from oxidative injury is mediated by leukemia inhibitory factor receptor (LIFR) and its ligands in the retina. Neurobiol Dis. 2009;34(3):535-44.